SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

(2022) Wanwisa Dejnirattisai et al.   CELL

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

(2022) Juan Manuel Carreño et al.   NATURE

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

(2022) Henning Gruell et al.   NATURE MEDICINE

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

(2022) Annika Rössler et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

(2022) Rolando Pajon et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

(2022) Dhiraj Mannar et al.   SCIENCE

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

(2022) Matthew McCallum et al.   SCIENCE

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

(2021) C. Garrett Rappazzo et al.   SCIENCE

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

(2021) Sabari Nath Neerukonda et al.   PLoS One

Brief report: Production of anti‐SARS‐CoV ‐2 hyperimmune globulin from convalescent plasma

(2021) Peter Vandeberg et al.   TRANSFUSION

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

(2021) Belinda M. Jackson-Thompson et al.   BMC INFECTIOUS DISEASES

Tackling COVID-19 with neutralizing monoclonal antibodies

(2021) Davide Corti et al.   CELL

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

(2021) Frauke Muecksch et al.   IMMUNITY

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

(2021) Ruoke Wang et al.   IMMUNITY

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

(2021) Jackson S. Turner et al.   NATURE

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

(2021) Michael Dougan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

(2021) Sophie M.-C. Gobeil et al.   SCIENCE

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

(2021) Sandro Halwe et al.   Viruses-Basel

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

(2021) Philip A. Mudd et al.   CELL

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

(2021) Markus Hoffmann et al.   CELL

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

(2021) Lu Lu et al.   CLINICAL INFECTIOUS DISEASES

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

(2021) Sabrina Lusvarghi et al.   JOURNAL OF VIROLOGY

Protection against Covid-19 by BNT162b2 Booster across Age Groups

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

(2021) Ital Nemet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

(2021) Fabian Schmidt et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment

(2021) Stephanie A Richard et al.   Open Forum Infectious Diseases

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

(2020) Alina Baum et al.   SCIENCE